 BEIJING, China CAMBRIDGE, Mass.--BUSINESS WIRE--- BGNE BTKi--BeiGene, Ltd. NASDAQ: BGNE; HKEX: 06160, a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Center for Drug Evaluation CDE of the China National Medical Products Administration NMPA has accepted a supplemental Biologics License Application sBLA for anti-PD-1 antibody tislelizumab for the treatment of patients with previously treated, locally advanced unresec 